The first in-human in vivo clinical trial using CRISPR-Cas9 is now open for enrollment; we take a closer look at this genome editing technology to understand its promising benefits as well as the potential challenges of anti-Cas9 immunity.
In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our team – including how she came to be our resident expert on IgE antibody testing on the ImmunoCAP platform.
We're looking forward to participating in several upcoming bioanalytical conferences and events this fall, ranging from small-circle workshops to global, world-renowned industry forums.
Platforms
Services